Alpha Tau Medical (NASDAQ:DRTS) Stock Falls 1% - Should You Sell?

Key Points

• Alpha Tau Medical shares fell 1% to $14.26 in Monday trading, with volume 41% below the average daily level.
• Analyst views remain mixed: Barclays raised its target to $30 and maintained an “overweight” rating, while Zacks Research downgraded the stock to “strong sell.” Overall, the consensus rating is “Hold” with an average target price of $15.40.
• The company reported a quarterly loss of $0.50 per share, missing the $0.14-per-share consensus estimate; analysts expect a full-year loss of approximately $1.05 per share.

Alpha Tau Medical Ltd. (NASDAQ:DRTS - Get Free Report)'s stock price was down 1% during trading on Monday. The company traded as low as $14.11 and last traded at $14.26. Approximately 281,414 shares changed hands during mid-day trading, a decline of 41% from the average daily volume of 476,393 shares. The stock had previously closed at $14.41.

Analysts Set New Price Targets

DRTS has been the topic of a number of research reports. Barclays raised their price target on Alpha Tau Medical from $17.00 to $30.00 and gave the stock an "overweight" rating in a report on Thursday, September 3rd. Benchmark restated a "buy" rating on shares of Alpha Tau Medical in a research report on Thursday, July 23rd. HC Wainwright upped their price objective on Alpha Tau Medical from $15.00 to $16.00 and gave the company a "buy" rating in a research note on Tuesday, August 11th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Alpha Tau Medical in a research report on Friday, July 17th. Finally, Zacks Research cut Alpha Tau Medical from a "hold" rating to a "strong sell" rating in a research report on Tuesday, September 1st. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat.com, Alpha Tau Medical currently has a consensus rating of "Hold" and an average target price of $15.40.

Alpha Tau Medical Trading Down 1.0%

The business's 50-day moving average is $14.48 and its two-hundred day moving average is $11.51. The company has a debt-to-equity ratio of 0.15, a quick ratio of 7.79 and a current ratio of 11.09. The stock has a market capitalization of $1.29 billion, a PE ratio of -13.71 and a beta of 1.22.

Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.36). As a group, equities research analysts anticipate that Alpha Tau Medical Ltd. will post -1.05 earnings per share for the current year.

Insider Buying and Selling at Alpha Tau Medical

In other news, CFO Raphi Levy sold 2,871 shares of Alpha Tau Medical stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $15.00, for a total value of $43,065.00. Following the sale, the chief financial officer owned 90,180 shares of the company's stock, valued at $1,352,700. The trade was a 3.09% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 39.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Alpha Tau Medical

A number of hedge funds have recently added to or reduced their stakes in the company. Everhart Financial Group Inc. acquired a new position in Alpha Tau Medical during the 2nd quarter worth approximately $126,000. Principal Financial Group Inc. purchased a new position in shares of Alpha Tau Medical during the 1st quarter worth approximately $132,000. Finally, Renaissance Technologies LLC purchased a new position in shares of Alpha Tau Medical during the 1st quarter worth approximately $286,000. Institutional investors and hedge funds own 2.65% of the company's stock.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd. is an Israel-based medical technology company focused on developing localized radiation treatments for solid tumors. Its lead technology, Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), is designed to deliver high-energy alpha radiation directly within a tumor while limiting exposure to surrounding healthy tissue.

Alpha DaRT uses implanted radium-224 sources that generate short-lived alpha-emitting atoms. These atoms diffuse through the treated tumor and can damage cancer cells over a localized area.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.